Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
10.90M | 9.56M | 9.22M | 9.33M | 6.79M | Gross Profit |
10.90M | 7.46M | 7.84M | 8.69M | -30.82M | EBIT |
-378.94M | -235.60M | -178.91M | -118.05M | -44.28M | EBITDA |
-378.94M | -233.50M | -177.53M | -117.41M | -43.77M | Net Income Common Stockholders |
-322.30M | -212.22M | -169.08M | -117.37M | -43.98M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
1.50B | 595.35M | 610.73M | 405.54M | 328.14M | Total Assets |
1.56B | 628.55M | 638.80M | 427.58M | 333.90M | Total Debt |
6.80M | 9.85M | 10.69M | 9.96M | 938.00K | Net Debt |
-213.07M | -175.23M | -329.71M | -395.58M | -327.20M | Total Liabilities |
138.94M | 127.79M | 60.73M | 46.15M | 27.68M | Stockholders Equity |
1.42B | 500.76M | 578.08M | 381.43M | 306.22M |
Cash Flow | Free Cash Flow | |||
-307.94M | -123.29M | -139.09M | -98.55M | -38.21M | Operating Cash Flow |
-300.87M | -119.06M | -136.27M | -94.81M | -37.12M | Investing Cash Flow |
-854.20M | -130.07M | -189.96M | -82.52M | -7.79M | Financing Cash Flow |
1.19B | 93.86M | 346.17M | 176.32M | 272.04M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
72 Outperform | $147.29B | 18.45 | 9.05% | 6.50% | 8.77% | 272.80% | |
49 Neutral | $5.25B | ― | -93.03% | ― | -10.48% | -18.79% | |
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
49 Neutral | $30.91B | ― | -414.62% | ― | 22.97% | 38.54% | |
48 Neutral | $13.03B | ― | -28.77% | ― | -52.75% | 25.00% | |
47 Neutral | $2.07B | ― | -600.68% | ― | -98.62% | -86.21% | |
36 Underperform | $3.56B | ― | -33.47% | ― | 13.99% | 0.17% |
Avidity Biosciences is making strides in precision cardiology with its development of AOC 1072 and AOC 1086, designed to target rare genetic cardiomyopathies by delivering siRNA directly to the heart muscle. These candidates demonstrated significant gene knockdown and safety in preclinical studies. The company also revealed next-generation RNA technology innovations promising enhanced delivery and durability, which could revolutionize treatment options for genetic cardiac diseases.